-
Featured
New Clues Emerge on Management of Recurrent Nonmuscle Invasive Bladder Cancer After Trimodality Therapy
When nonmuscle invasive bladder cancer develops after trimodality therapy for muscle invasive bladder cancer, salvage radical cystectomy isn't necessarily required, researchers have found.
-
Featured
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates
Physicians at Massachusetts General Hospital are in the early stages of testing a novel regimen for patients with muscle-invasive urothelial bladder cancer who are medically unfit for radical cystectomy or platinum-based radiosensitizing chemotherapy.
-
Featured
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
Orthotopic neobladder reconstruction is becoming the diversion procedure of choice for female cystectomy patients due to recent advances in care for female urology patients.
-
Review: Molecular Biomarkers May Lead to Personalized Treatment of Muscle-invasive Bladder Cancer
Rapidly emerging molecular biomarkers will allow oncologists to choose more confidently between radical cystectomy and trimodality therapy for patients with muscle-invasive bladder cancer, as well as identify which patients undergoing trimodality therapy are likely to benefit from adding immunotherapy.
-
Stress-Inducible Gene May Promote Aggressive Bladder Cancer
A team including Massachusetts General Hospital researchers have found that a stress-inducible gene known as IER3 seems to promote aggressive progression of bladder cancer.
-
SRPK2 May Have Key Role in Prostate Cancer Progression and Metastasis
Urologists have demonstrated for the first time that SRPK2, a cell-cycle regulator protein, is upregulated in human prostate cancer and contributes to disease progression and metastasis.
Bladder contributors
-
Chin-Lee Wu, MD, PhD
Associate Pathologist, Massachusetts General Hospital, Associate Professor of Pathology, Harvard Medical School, Director, Genitourinary Pathology Services
Recent Article
New Target Discovered for Prostate Cancer Immunotherapy -
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Associate Professor, Harvard Medical School
Recent Article
Noninvasive Assay Predicts Drug Response, Early Dissemination in Prostate Cancer
-
Jason A. Efstathiou, MD, Dphil
Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic
Recent Article
Review: Molecular Biomarkers May Lead to Personalized Treatment of Muscle-invasive Bladder Cancer -
Marc Dror Michaelson, MD, PhD
Clinical Director, Genitourinary Cancer Center
Recent Article
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates -
Matthew F. Wszolek, MD
Assistant in Urology, Massachusetts General Hospital, Instructor in Surgery, Harvard Medical School
Recent Article
New Clues Emerge on Management of Recurrent Nonmuscle Invasive Bladder Cancer After Trimodality Therapy
-
Michael L. Blute, MD
Chief, Department of Urology, Walter S. Kerr, Jr., Professor of Surgery, Harvard Medical School
Recent Article
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
-
William Shipley, MD
Andres Soriano Distinguished Professor of Radiation Oncology, Harvard Medical School
Recent Article
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.Resource Links
